HCPCS Level II code J0224 denotes the injectable drug lumasiran in 0.5 mg units and is used to bill for the medication component of patient care when lumasiran is administered. Lumasiran is a targeted RNA therapy with specific clinical indications, and accurate coding is essential for drug inventory, payer adjudication, and national monitoring of specialty pharmaceutical utilization. This code matters nationally as specialty injectables represent a growing share of drug spend and require precise HCPCS reporting for coverage determinations and Medicare program oversight. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical and billing context, typical sites of service where lumasiran is administered, and which payers are included in the coverage review. The publication also outlines what to expect in related benchmark and policy sections, including coverage and utilization benchmarks, coding guidance updates, and the clinical setting for administration. Data not available in the input for associated taxonomies, ICD-10 diagnoses, or payer-specific policy details are noted where appropriate.